Intra-Cellular Therapies Inc. filed lawsuits seeking to block copies of Caplyta proposed by Sandoz Group and six other generic-drug makers, alleging infringement of as many as 16 patents for the bipolar depression and schizophrenia treatment.
The asserted patents cover compositions and methods for treating sleep disorders and other disorders using lumateperone, according to complaints filed Wednesday against
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.